SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
of Report (Date of earliest event reported): June 5, 2020
(Exact name of registrant as specified in its charter)
or other jurisdiction
W. 6th Ave., #400
of principal executive offices)
telephone number, including area code)
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
pursuant to Section 12(b) of the Act: None
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
growth company [X]
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Current Report on Form 8-K/A (this “Amendment”) is being filed by OncBioMune Pharmaceuticals, Inc., a Nevada corporation
(the “Company”), to amend its Current Report on Form 8-K (the “Prior 8-K”) filed with the Securities and
Exchange Commission (the “SEC”) on June 11, 2020, in connection with the consummation on June 5, 2020 of the transactions
contemplated by that certain Asset Purchase Agreement dated May 12, 2020 (the “Asset Purchase Agreement”), between
the Company and Avant Diagnostics, Inc. (“Avant”). At the closing, the Company acquired substantially all of the assets
of Avant and assumed certain of its liabilities (the “Asset Sale Transaction”).
Company is filing this Amendment solely to provide (i) the historical audited financial statements of Avant as of and for the
years ended September 30, 2019 and 2018, and the unaudited condensed consolidated financial statements as of March 31, 2020 and
for the three and six month periods ended March 31, 2020 and 2019, referred to in Item 9.01(a) below; and (ii) the unaudited pro
forma condensed combined financial statements as of and for the three month period ended March 31, 2020 and for the year ended
December 31, 2019, referred to in Item 9.01(b) below. Except for the foregoing, this Amendment does not modify or update any other
disclosure contained in the Prior 8-K. Such financial information was excluded from the Prior 8-K in reliance on the instructions
to such items.
9.01 Financial Statements and Exhibits
Financial Statements of Business Acquired
audited financial statements of Avant as of and for the years ended September 30, 2019 and 2018, and the unaudited condensed consolidated
financial statements as of March 31, 2020 and for the three and six month periods ended March 31, 2020 and 2019, are filed herewith
as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference.
Pro Forma Financial Information.
unaudited pro forma condensed financial statements of the Company and Avant as of and for the three month period ended March 31,
2020 and for the year ended December 31, 2019, filed herewith and attached hereto as Exhibit 99.3, are incorporated herein by
is a list of exhibits included with this Current Report on Form 8-K.
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Chief Financial Officer|
August 19, 2020